TrialJournal of atherosclerosis and thrombosis2025

Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study.

Hidenori Arai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.